Clinical trials: Lymphoma, Hodgkins
Relapsed Non-Hodgkin Lymphoma
Tumor Microenvironment Mechanism of LY007 for r/r B-NHL and the Exploration of Novel CAR-T Translational Research
The T cell characteristics of 12 patients treated with CD20 CAR-T (LY007 cell injection) were analyzed to study their relationship with CAR-T anti-tumor activity, tumor killing, and in vivo proliferation, and to explore the…
- Trial name
- NCT06049381
- Volunteers
- 22 people
- Sponsor
- Ruijin Hospital
Non-Hodgkin's Lymphoma, Leukemia
Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT
One of two different doses of thymoglobulin will allow bone marrow engraftment with minimal Graft-versus-Host Disease and allow adequate immune response to allow the transplanted stem cells to replace the tumor cells.
- Conditions
- Non-Hodgkin's Lymphoma, Leukemia, Multiple Myeloma, Acute Myeloid Leukemia
- Trial name
- NCT00709592
- Testing
- Thymoglobulin, Total-Body Irradiation, Allogeneic PBSCT or BMT
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Virginia Commonwealth University
B-cell Small Lymphocytic Lymphoma Recurrent
A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma
This was a Phase 1 multicenter study of bendamustine, rituximab and TRU-016 (BRT) in subjects with relapsed indolent B-cell lymphoma.
- Trial name
- NCT01317901
- Testing
- TRU-016, Bendamustine, Rituximab
- Where
- 6 sites in United States
- Volunteers
- 12 people
- Sponsor
- Aptevo Therapeutics
Non Hodgkin Lymphoma
Auto/Allo Tandem Transplant for Relapsed B-NHL
The investigators plan to perform a retrospective review of patients with poor risk relapsed/refractory B-NHL having received HSCT and targeted immunotherapy at the Maria Fareri Children's Hospital between January 1, 2012 and…
- Trial name
- NCT03205657
- Testing
- auto transplant followed by allo transplant
- Volunteers
- 12 people
- Sponsor
- New York Medical College
Non Hodgkin's Lymphoma, NHL
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
The goal of this study is to evaluate a new approach to immunotherapy in NHL by combining two antibodies, veltuzumab and epratuzumab.
- Conditions
- Non Hodgkin's Lymphoma, NHL, Aggressive NHL, Diffuse Large B-cell Lymphoma
- Trial name
- NCT01101581
- Testing
- Veltuzumab and 90Y-Epratuzumab Tetraxetan, 90Y-epratuzumab tetraxetan, veltuzumab
- Where
- 7 sites in United States
- Sponsor
- Gilead Sciences
Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral
Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma
This study is investigating the combination of Brentuximab vedotin and lenalidomide in the treatment of relapsed/refractory peripheral T cell lymphoma or cutaneous T cell lymphoma or Hodgkin lymphoma.
- Conditions
- Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hodgkin Lymphoma
- Trial name
- EpiBrentlen (NCT03302728)
- Testing
- Lenalidomide 15mg, Brentuximab Vedotin 1.8 mg/Kg
- Where
- Australia
- Volunteers
- 6 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
This phase I/Ib trial investigates the side effects of CC-486 and how well it works in combination with lenalidomide and obinutuzumab in treating patients with CD20 positive B-cell lymphoma that has come back (recurrent) or has…
- Conditions
- Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Mucosa-Associated Lymphoid Tissue Lymphoma
- Trial name
- NCT04578600
- Testing
- Lenalidomide, Obinutuzumab, Oral Azacitidine
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Joseph Tuscano
B-cell Non Hodgkin Lymphoma
CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors
Clinical trial for the safety and efficacy of CD19 CAR-T following autologous hematopoietic stem cell transplantation (ASCT) for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) with High-Risk Prognostic Factors
- Trial name
- NCT06365671
- Testing
- autologous stem-cell transplantation, Relmacabtagene autoleucel (relma-cel)
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Ruijin Hospital
Hodgkin´s Lymphoma
Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma
This study is designed to test (1) feasibility and efficiancy of new BACOPP regimen and (2) toxicity, overall response and FFTF.
- Trial name
- NCT00284271
- Testing
- Cyclophosphamide, Adramycin, Procarbacine
- Where
- Germany
- Volunteers
- 65 people
- Sponsor
- University of Cologne
Non-hodgkin Lymphoma
Dietary Milled Seed Mix in Patients With Non-Hodgkin Lymphoma
Recent literature data suggest beneficial effects of dietary fats in patients with cancers, in particular polyunsaturated fatty acids (PUFAs).
- Trial name
- Lymphoseed (NCT03260231)
- Testing
- Milled seed mix
- Where
- Serbia
- Volunteers
- 40 people
- Sponsor
- University of Belgrade
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma
Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies
This study is to evaluate the highest tolerated dose, safety and activity of HCD122 in adults with non-Hodgkin's or Hodgkin's lymphoma who have received at least two prior therapies.
- Trial name
- NCT00670592
- Testing
- HCD122
- Where
- 28 sites in United States, Australia and 9 more
- Volunteers
- 111 people
- Sponsor
- Novartis Pharmaceuticals
Lymphoma
Combination Chemotherapy With or Without Rituximab in Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver…
- Trial name
- IDEC-C2B8 (NCT00064116)
- Testing
- rituximab, CHOP regimen
- Where
- 25 sites in Canada
- Volunteers
- 824 people
- Sponsor
- NCIC Clinical Trials Group
Large B-cell Lymphoma, Lymphoma, B-Cell
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma…
- Conditions
- Large B-cell Lymphoma, Lymphoma, B-Cell, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
- Trial name
- PiNACLE-H2H (NCT07188558)
- Testing
- rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel
- Where
- 36 sites in United States
- Volunteers
- 400 people
- Sponsor
- Lyell Immunopharma, Inc.
NHL, Multiple Myeloma
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without…
- Conditions
- NHL, Multiple Myeloma, Blood Cancer, Refractory Non-Hodgkin Lymphoma
- Trial name
- NCT06119685
- Testing
- IDP-023, Rituximab, Daratumumab
- Where
- 12 sites in United States
- Volunteers
- 128 people
- Sponsor
- Indapta Therapeutics, INC.
Lymphoma, Small Intestine Cancer
Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Irinotecan may be effective in treating patients with abnormal liver or kidney function or who have received…
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00003368
- Testing
- irinotecan hydrochloride
- Where
- 45 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma
To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)
A Phase II Open-Label Single-arm Study to Evaluate Safety and Efficacy of locally manufactured autologous CD19-directed CAR T-cells in Patients with Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL) or patients not eligible for…
- Trial name
- CAR-T for NHL (NCT06698484)
- Testing
- CAR-T cells
- Where
- Malaysia
- Volunteers
- 20 people
- Sponsor
- National University of Malaysia
Pediatric Hodgkin's Disease
Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation.
This trial proposes a therapy for pediatric Hodgkin lymphoma with the objective of achieving high levels of long lasting complete remission with less risk of late effects.
- Trial name
- LHGALOP2017 (NCT03500133)
- Testing
- No radiotherapy if CR at the end of chemotherapy., Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered., Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.
- Where
- Argentina
- Volunteers
- 500 people
- Sponsor
- Hospital JP Garrahan
Classical Hodgkin Lymphoma
Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents
The EuroNet-PHL-C2 trial is an international, multicentre, randomised controlled trial with the aims to reduce the indication for radiotherapy in newly diagnosed patients with classical Hodgkin lymphoma without compromising cure…
- Trial name
- NCT02684708
- Testing
- cyclophosphamide, vincristine, prednisone, dacarbazine, cyclo, vcr, pred, dacarb,etop and doxo
- Where
- 19 sites in Australia, Austria and 17 more
- Volunteers
- 2,921 people
- Sponsor
- University of Giessen
Non Hodgkin Lymphoma
A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
ONO-7018 is a selective inhibitor of mucosa associated lymphoid tissue protein 1 (MALT1) and is expected to exhibit antitumor activity in NHL.
- Trial name
- NCT06622226
- Testing
- ONO-7018
- Where
- 6 sites in Japan
- Volunteers
- 2 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy
A study of CT-RD06 cell injection in patients with relapsed or refractory CD19+ B-cell hematological malignancy.
- Trial name
- NCT04226989
- Testing
- CT-RD06
- Where
- China
- Volunteers
- 72 people
- Sponsor
- He Huang
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.